BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baldwin AG, Rivers-Auty J, Daniels MJD, White CS, Schwalbe CH, Schilling T, Hammadi H, Jaiyong P, Spencer NG, England H. Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chem Biol. 2017;24:1321-1335.e5. [PMID: 28943355 DOI: 10.1016/j.chembiol.2017.08.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Fernandes GFS, Denny WA, Dos Santos JL. Boron in drug design: Recent advances in the development of new therapeutic agents. Eur J Med Chem 2019;179:791-804. [PMID: 31288128 DOI: 10.1016/j.ejmech.2019.06.092] [Cited by in Crossref: 48] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
2 Soriano-ursúa MA, Farfán-garcía ED, Geninatti-crich S. Turning Fear of Boron Toxicity into Boron-containing Drug Design. CMC 2019;26:5005-18. [DOI: 10.2174/0929867326666190327154954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
3 Hoyle C, Redondo-Castro E, Cook J, Tzeng TC, Allan SM, Brough D, Lemarchand E. Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture. Immunology 2020;161:39-52. [PMID: 32445196 DOI: 10.1111/imm.13221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang X, Xu A, Lv J, Zhang Q, Ran Y, Wei C, Wu J. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur J Med Chem 2020;185:111822. [PMID: 31699536 DOI: 10.1016/j.ejmech.2019.111822] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
5 Agarwal S, Pethani JP, Shah HA, Vyas V, Sasane S, Bhavsar H, Bandyopadhyay D, Giri P, Viswanathan K, Jain MR, Sharma R. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor. Bioorg Med Chem Lett 2020;30:127571. [PMID: 32980515 DOI: 10.1016/j.bmcl.2020.127571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Huang S, Che J, Chu Q, Zhang P. The Role of NLRP3 Inflammasome in Radiation-Induced Cardiovascular Injury. Front Cell Dev Biol 2020;8:140. [PMID: 32226786 DOI: 10.3389/fcell.2020.00140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
7 Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 2020;6:36. [PMID: 32550001 DOI: 10.1038/s41421-020-0167-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 80.0] [Reference Citation Analysis]
8 Hafner-bratkovič I, Pelegrín P. Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation. Current Opinion in Immunology 2018;52:8-17. [DOI: 10.1016/j.coi.2018.03.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
9 Wang X, Liu Y, Han X, Zou G, Zhu W, Shen H, Liu H. Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors. Bioorg Med Chem Lett 2021;44:128101. [PMID: 33984476 DOI: 10.1016/j.bmcl.2021.128101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gong T, Yang Y, Jin T, Jiang W, Zhou R. Orchestration of NLRP3 Inflammasome Activation by Ion Fluxes. Trends Immunol 2018;39:393-406. [PMID: 29452983 DOI: 10.1016/j.it.2018.01.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 23.3] [Reference Citation Analysis]
11 Hörauf JA, Kany S, Janicova A, Xu B, Vrdoljak T, Sturm R, Dunay IR, Martin L, Relja B. Short Exposure to Ethanol Diminishes Caspase-1 and ASC Activation in Human HepG2 Cells In Vitro. Int J Mol Sci 2020;21:E3196. [PMID: 32366053 DOI: 10.3390/ijms21093196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Swanton T, Beswick JA, Hammadi H, Morris L, Williams D, de Cesco S, El-Sharkawy L, Yu S, Green J, Davis JB, Lawrence CB, Brough D, Freeman S. Selective inhibition of the K+ efflux sensitive NLRP3 pathway by Cl- channel modulation. Chem Sci 2020;11:11720-8. [PMID: 34094411 DOI: 10.1039/d0sc03828h] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gritsenko A, Yu S, Martin-Sanchez F, Diaz-Del-Olmo I, Nichols EM, Davis DM, Brough D, Lopez-Castejon G. Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro. Front Immunol 2020;11:565924. [PMID: 33101286 DOI: 10.3389/fimmu.2020.565924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
14 Harrison D, Boutard N, Brzozka K, Bugaj M, Chmielewski S, Cierpich A, Doedens JR, Fabritius CRY, Gabel CA, Galezowski M, Kowalczyk P, Levenets O, Mroczkowska M, Palica K, Porter RA, Schultz D, Sowinska M, Topolnicki G, Urbanski P, Woyciechowski J, Watt AP. Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors. Bioorg Med Chem Lett 2020;30:127560. [PMID: 32956781 DOI: 10.1016/j.bmcl.2020.127560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 2018;17:588-606. [PMID: 30026524 DOI: 10.1038/nrd.2018.97] [Cited by in Crossref: 375] [Cited by in F6Publishing: 328] [Article Influence: 125.0] [Reference Citation Analysis]
16 Swanton T, Cook J, Beswick JA, Freeman S, Lawrence CB, Brough D. Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery? SLAS Discov 2018;23:991-1017. [PMID: 29969573 DOI: 10.1177/2472555218786210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Baldwin AG, Tapia VS, Swanton T, White CS, Beswick JA, Brough D, Freeman S. Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome. ChemMedChem 2018;13:312-20. [PMID: 29331080 DOI: 10.1002/cmdc.201700731] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
18 Wei H, Davies JE, Harper MT. 2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets. Cell Death Discov 2020;6:10. [PMID: 32140260 DOI: 10.1038/s41420-020-0244-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Tapia VS, Daniels MJD, Palazón-Riquelme P, Dewhurst M, Luheshi NM, Rivers-Auty J, Green J, Redondo-Castro E, Kaldis P, Lopez-Castejon G, Brough D. The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes. J Biol Chem 2019;294:8325-35. [PMID: 30940725 DOI: 10.1074/jbc.RA119.008009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
20 Green JP, Yu S, Martín-Sánchez F, Pelegrin P, Lopez-Castejon G, Lawrence CB, Brough D. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc Natl Acad Sci U S A 2018;115:E9371-80. [PMID: 30232264 DOI: 10.1073/pnas.1812744115] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
21 Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK. Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease. Mov Disord 2020;35:20-33. [PMID: 31680318 DOI: 10.1002/mds.27874] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
22 Zito G, Buscetta M, Cimino M, Dino P, Bucchieri F, Cipollina C. Cellular Models and Assays to Study NLRP3 Inflammasome Biology. Int J Mol Sci 2020;21:E4294. [PMID: 32560261 DOI: 10.3390/ijms21124294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
23 Hugelshofer CL, Palani V, Sarpong R. Calyciphylline B-type Alkaloids: Evolution of a Synthetic Strategy to (−)-Daphlongamine H. J Org Chem 2019;84:14069-91. [DOI: 10.1021/acs.joc.9b02223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
24 Romero-Aguilar KS, Arciniega-Martínez IM, Farfán-García ED, Campos-Rodríguez R, Reséndiz-Albor AA, Soriano-Ursúa MA. Effects of boron-containing compounds on immune responses: review and patenting trends. Expert Opin Ther Pat 2019;29:339-51. [PMID: 31064237 DOI: 10.1080/13543776.2019.1612368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Rivers-Auty J, Tapia VS, White CS, Daniels MJD, Drinkall S, Kennedy PT, Spence HG, Yu S, Green JP, Hoyle C, Cook J, Bradley A, Mather AE, Peters R, Tzeng TC, Gordon MJ, Beattie JH, Brough D, Lawrence CB. Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation. J Neurosci 2021;41:3025-38. [PMID: 33597269 DOI: 10.1523/JNEUROSCI.1980-20.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med 2019;11:e10248. [PMID: 31015277 DOI: 10.15252/emmm.201810248] [Cited by in Crossref: 163] [Cited by in F6Publishing: 148] [Article Influence: 163.0] [Reference Citation Analysis]
27 Vasconcelos DP, Águas AP, Barbosa MA, Pelegrín P, Barbosa JN. The inflammasome in host response to biomaterials: Bridging inflammation and tissue regeneration. Acta Biomater 2019;83:1-12. [PMID: 30273748 DOI: 10.1016/j.actbio.2018.09.056] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
28 Agarwal S, Sasane S, Shah HA, Pethani JP, Deshmukh P, Vyas V, Iyer P, Bhavsar H, Viswanathan K, Bandyopadhyay D, Giri P, Mahapatra J, Chatterjee A, Jain MR, Sharma R. Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors. ACS Med Chem Lett 2020;11:414-8. [PMID: 32292543 DOI: 10.1021/acsmedchemlett.9b00433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
29 Marchetti C. The NLRP3 Inflammasome as a Pharmacological Target. J Cardiovasc Pharmacol 2019;74:285-96. [PMID: 31335445 DOI: 10.1097/FJC.0000000000000718] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 12.0] [Reference Citation Analysis]
30 Herman FJ, Pasinetti GM. Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Brain Behav Immun 2018;73:66-84. [PMID: 29902514 DOI: 10.1016/j.bbi.2018.06.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
31 Angosto-Bazarra D, Molina-López C, Peñín-Franch A, Hurtado-Navarro L, Pelegrín P. Techniques to Study Inflammasome Activation and Inhibition by Small Molecules. Molecules 2021;26:1704. [PMID: 33803783 DOI: 10.3390/molecules26061704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 2019;19:477-89. [PMID: 31036962 DOI: 10.1038/s41577-019-0165-0] [Cited by in Crossref: 730] [Cited by in F6Publishing: 626] [Article Influence: 730.0] [Reference Citation Analysis]
33 Bertinaria M, Gastaldi S, Marini E, Giorgis M. Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. Arch Biochem Biophys 2019;670:116-39. [PMID: 30448387 DOI: 10.1016/j.abb.2018.11.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
34 Baldwin AG, Bevan J, Brough D, Ledder R, Freeman S. Synthesis and antibacterial activities of enamine derivatives of dehydroacetic acid. Med Chem Res 2018;27:884-9. [PMID: 29527108 DOI: 10.1007/s00044-017-2110-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
35 Pelegrin P. P2X7 receptor and the NLRP3 inflammasome: Partners in crime. Biochem Pharmacol 2021;187:114385. [PMID: 33359010 DOI: 10.1016/j.bcp.2020.114385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
36 Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20. [PMID: 31284572 DOI: 10.3390/ijms20133328] [Cited by in Crossref: 410] [Cited by in F6Publishing: 328] [Article Influence: 205.0] [Reference Citation Analysis]
37 Shin JN, Rao L, Sha Y, Abdel Fattah E, Hyser J, Eissa NT. p38 MAPK Activity Is Required to Prevent Hyperactivation of NLRP3 Inflammasome. J Immunol 2021:ji2000416. [PMID: 34193605 DOI: 10.4049/jimmunol.2000416] [Reference Citation Analysis]
38 Liu Y, Li C, Yin H, Zhang X, Li Y. NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis. Evid Based Complement Alternat Med 2020;2020:1561342. [PMID: 32328119 DOI: 10.1155/2020/1561342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Palazon-Riquelme P, Lopez-Castejon G. The inflammasomes, immune guardians at defence barriers. Immunology 2018;155:320-30. [PMID: 30098204 DOI: 10.1111/imm.12989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
40 Wu J, Sun J, Meng X. Pyroptosis by caspase-11 inflammasome-Gasdermin D pathway in autoimmune diseases. Pharmacol Res 2021;165:105408. [PMID: 33412278 DOI: 10.1016/j.phrs.2020.105408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Redondo-Castro E, Faust D, Fox S, Baldwin AG, Osborne S, Haley MJ, Karran E, Nuthall H, Atkinson PJ, Dawson LA, Routledge C, Allan SM, Freeman S, Brownlees J, Brough D. Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Sci Rep 2018;8:5667. [PMID: 29618797 DOI: 10.1038/s41598-018-24029-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
42 Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:128. [PMID: 30755589 DOI: 10.1038/s41419-019-1413-8] [Cited by in Crossref: 314] [Cited by in F6Publishing: 272] [Article Influence: 157.0] [Reference Citation Analysis]